IGI Laboratories (IG) Submits 5th Abbreviated New Drug Application with FDA in 2011
Tweet
Share
E-mailGet Alerts IG Hot Sheet
Join SI Premium – FREE
IGI Laboratories, Inc. (NYSE: IG) today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five.
IGI President and CEO Charlie Moore commented, “We are excited to have one additional ANDA filing for 2011. We now have five ANDAs on file with the US FDA, and we are poised to deliver a strong product development performance in 2012. ANDAs are the key to the future at IGI and our development team remains focused and motivated.” The development of ANDA products has successfully been integrated into the Company’s ongoing contract services business.
IGI President and CEO Charlie Moore commented, “We are excited to have one additional ANDA filing for 2011. We now have five ANDAs on file with the US FDA, and we are poised to deliver a strong product development performance in 2012. ANDAs are the key to the future at IGI and our development team remains focused and motivated.” The development of ANDA products has successfully been integrated into the Company’s ongoing contract services business.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
